65,437 trials
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm · Nasal Vestibulitis
Primary: Response — 2; 4; 1; 12 Participants
Nasal Polyps
Primary: Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read) — -0.6; 0.2 Scores on a Scale — p=<0.001
Leukemia
Primary: Percentage of Patients With Disease Free Survival — 65.8 percentage of paticipants
Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) — 50.6 Percentage of participants
Metastatic Solid Tumors · Treatment-Refractory Cancers
Primary: Maximum Tolerated Dose (MTD) at Which Dose-Limiting Toxicities (DLT) Occurred With rhIL-15 Administered in Combination With Fixed Doses of Nivolumab and Ipilimumab — 1.0…
HIV-1-infection on Healthy Volunteers
Primary: Change in Insulin Sensitivity in Participants From Baseline to End of Study Between Two Crossover Groups. — 7.749985; 6.286017; 8.716221; 6.815305 (mg/kg/min)
Bidirectional Endoscopy
Primary: Modified Observer's Assessment of Alertness/Sedation Scale, MOAA/S — 0.674; 0.449; 0.937 units on a scale
Renal Cancer · Tumor, Solid · Kidney Cancer
Primary: Primary Effectiveness: Technical Success — 100.0 percentage of tumors
Urothelial Cancer
Primary: Real-World Overall Survival — 16.8 months
Cancer · Adherence, Medication
Primary: Enrollment Rate — 70 Participants
Autism Spectrum Disorder · Insomnia
Primary: Change in Children's Sleep Habits Questionnaire (CSHQ) — -8.78; -.59 units on a scale
Passiv Continuous Patella Mobilisation
Primary: Patellofemoral Translation — 0.819; 0.734; 0.776; 0.771 cm
Psoriatic Arthritis
Primary: Psoriatic Arthritis Disease Activity Score (PASDAS) at 24 Weeks — 3.09; 2.70 score on a scale — p=0.064
Depression, Unipolar · Posttraumatic Stress Disorder · Trauma
Primary: Number of Participants With Major Depression at End of Treatment — 127; 89; 6; 11 Participants
Venous Leg Ulcer · Diabetic Foot
Primary: Effectiveness of AQUACEL® Ag+ Extra™ and Cutimed® Sorbact® on Wound Management — 80; 60 Number of Wounds